Panacea Biotec Reports Strong Sales Growth Amid Liquidity Challenges in August 2025

Panacea Biotec, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending June 2025. The results, declared on August 14, 2025, indicate a notable shift in the company's evaluation, with the score moving to 2 from -10 over the past three months. The financial data reveals that Panacea Biotec achieved net sales of Rs 166.70 crore for the quarter, reflecting a year-on-year growth of 44.05%. This marks the highest quarterly sales figure the company has recorded in the last five quarters, suggesting a positive near-term sales trend. However, the financial results also highlight challenges for the company. The cash and cash equivalents for the half-yearly period have reached their lowest point in the last six periods, indicating a decline in short-term liquidity. Overall, the financial results present a mixed picture for Panacea Biotec, with significant sales growth juxtaposed against liquidity concerns. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.